We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
NewLink Genetics to Present Phase 2 Data of its HyperAcute® Pancreas Immunotherapy
News

NewLink Genetics to Present Phase 2 Data of its HyperAcute® Pancreas Immunotherapy

NewLink Genetics to Present Phase 2 Data of its HyperAcute® Pancreas Immunotherapy
News

NewLink Genetics to Present Phase 2 Data of its HyperAcute® Pancreas Immunotherapy

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "NewLink Genetics to Present Phase 2 Data of its HyperAcute® Pancreas Immunotherapy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

NewLink Genetics Corporation has announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California. A summary of the poster is below.

Title: Effect of the addition of algenpantucel-L immunotherapy to standard adjuvant therapy on survival in patients with resected pancreas cancer

• General Poster Session B, Friday January 21, 2011, 11:45 AM - 1:15 PM Pacific Time

• Abstract # 236, (poster board A85)

• First Author: Dr. Jeffrey M. Hardacre, University Hospitals Case Medical Center, Cleveland, Ohio

The open-label, non randomized, multicenter Phase 2 clinical trial included 70 patients with surgically resectable pancreatic cancer who received the HyperAcute Pancreas immunotherapy in combination with standard adjuvant chemotherapy. The primary objective of the study was disease-free survival at 12 months.

Based on positive data from this Phase 2 clinical trial, NewLink is currently enrolling a nationwide Phase 3 clinical trial of HyperAcute Pancreas cancer immunotherapy in patients who have successfully undergone pancreatic surgical resection. The U.S. Food and Drug Administration (FDA) has granted both Fast Track designation and Orphan Drug designation for this program.

Advertisement